199 related articles for article (PubMed ID: 36203459)
1. KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib
Jiang L; Liu Y; Su X; Wang J; Zhao Y; Tumbath S; Kilgore JA; Williams NS; Chen Y; Wang X; Mendonca MS; Lu T; Fu YX; Huang X
Front Oncol; 2022; 12():976292. PubMed ID: 36203459
[TBL] [Abstract][Full Text] [Related]
2. DNA damage induced by KP372-1 hyperactivates PARP1 and enhances lethality of pancreatic cancer cells with PARP inhibition.
Viera T; Patidar PL
Sci Rep; 2020 Nov; 10(1):20210. PubMed ID: 33214574
[TBL] [Abstract][Full Text] [Related]
3. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
[TBL] [Abstract][Full Text] [Related]
4. Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Huang X; Motea EA; Moore ZR; Yao J; Dong Y; Chakrabarti G; Kilgore JA; Silvers MA; Patidar PL; Cholka A; Fattah F; Cha Y; Anderson GG; Kusko R; Peyton M; Yan J; Xie XJ; Sarode V; Williams NS; Minna JD; Beg M; Gerber DE; Bey EA; Boothman DA
Cancer Cell; 2016 Dec; 30(6):940-952. PubMed ID: 27960087
[TBL] [Abstract][Full Text] [Related]
5. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
[TBL] [Abstract][Full Text] [Related]
6. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
7. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.
Chakrabarti G; Silvers MA; Ilcheva M; Liu Y; Moore ZR; Luo X; Gao J; Anderson G; Liu L; Sarode V; Gerber DE; Burma S; DeBerardinis RJ; Gerson SL; Boothman DA
Sci Rep; 2015 Nov; 5():17066. PubMed ID: 26602448
[TBL] [Abstract][Full Text] [Related]
8. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
Kim DS; Camacho CV; Kraus WL
Exp Mol Med; 2021 Jan; 53(1):42-51. PubMed ID: 33487630
[TBL] [Abstract][Full Text] [Related]
9. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation.
Dong Y; Bey EA; Li LS; Kabbani W; Yan J; Xie XJ; Hsieh JT; Gao J; Boothman DA
Cancer Res; 2010 Oct; 70(20):8088-96. PubMed ID: 20940411
[TBL] [Abstract][Full Text] [Related]
11. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
Nizialek E; Antonarakis ES
Cancer Manag Res; 2020; 12():8105-8114. PubMed ID: 32982407
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
Chu YY; Yam C; Yamaguchi H; Hung MC
J Biomed Sci; 2022 Oct; 29(1):86. PubMed ID: 36284291
[TBL] [Abstract][Full Text] [Related]
13. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
[TBL] [Abstract][Full Text] [Related]
14. Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair.
Bentle MS; Reinicke KE; Bey EA; Spitz DR; Boothman DA
J Biol Chem; 2006 Nov; 281(44):33684-96. PubMed ID: 16920718
[TBL] [Abstract][Full Text] [Related]
15. Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.
Kanakkanthara A; Hou X; Ekstrom TL; Zanfagnin V; Huehls AM; Kelly RL; Ding H; Larson MC; Vasmatzis G; Oberg AL; Kaufmann SH; Mansfield AS; Weroha SJ; Karnitz LM
Cancer Res; 2022 Jan; 82(2):307-319. PubMed ID: 34810199
[TBL] [Abstract][Full Text] [Related]
16. The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.
Pham MM; Hinchcliff E; Avila M; Westin SN
Cancer J; 2021 Nov-Dec 01; 27(6):491-500. PubMed ID: 34904812
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
Xiong J; Barayan R; Louie AV; Lok BH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
[TBL] [Abstract][Full Text] [Related]
18. HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer.
Ma H; Qi G; Han F; Lu W; Peng J; Li R; Yan S; Yuan C; Kong B
Cell Death Dis; 2022 Mar; 13(3):263. PubMed ID: 35332131
[TBL] [Abstract][Full Text] [Related]
19. DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy.
Nguyen NT; Pacelli A; Nader M; Kossatz S
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267438
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitors in metastatic prostate cancer.
Taylor AK; Kosoff D; Emamekhoo H; Lang JM; Kyriakopoulos CE
Front Oncol; 2023; 13():1159557. PubMed ID: 37168382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
